Rankings
▼
Calendar
INMB FY 2024 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena
INMB
INmune Bio, Inc.
$35M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$14,000
-91.0% YoY
Gross Profit
$14,000
100.0% margin
Operating Income
-$43M
-304535.7% margin
Net Income
-$42M
-300585.7% margin
EPS (Diluted)
$-2.11
Cash Flow
Operating Cash Flow
-$33M
Free Cash Flow
-$33M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$40M
Total Liabilities
$7M
Stockholders' Equity
$32M
Cash & Equivalents
$21M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$14,000
$155,000
-91.0%
Gross Profit
$14,000
$155,000
-91.0%
Operating Income
-$43M
-$30M
-43.4%
Net Income
-$42M
-$30M
-40.2%
← Q4 2023
All Quarters
Q1 2024 →